Concepedia

Jad Bsat

JB

Statistics

Publications

8

Citations

470

H-Index

8

Active since

2016

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

Brigham and Women's Hospital

Memorial Sloan Kettering Cancer Center

Jad Bsat is an author at Dana-Farber Cancer Institute specializing in immunology, medicine, and oncology.

Top concepts

Publications per year

2016–2020

8

Publications

8

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Philippe Armand, Yi‐Bin Chen, Robert Redd et al. · Blood · 2019 · 178 citations · Full text

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Matthew S. Davids, Danielle M. Brander, Haesook T. Kim et al. · The Lancet Haematology · 2019 · 70 citations · Full text

, , +11

A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma

Philippe Armand, Robert Redd, Jad Bsat et al. · British Journal of Haematology · 2016 · 65 citations · Full text

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Matthew J. Frigault, Philippe Armand, Robert Redd et al. · Blood Advances · 2020 · 65 citations · Full text

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Reid W. Merryman, Natasha Edwin, Robert Redd et al. · Blood Advances · 2020 · 53 citations · Full text

, , +16

1–5 of 8